THE HYDROXYCHLOROQUINE (HCQ) story got a major plot twist on May 25. Two months after US President Donald Trump waxed eloquent on the benefits of the antimalarial drug in treating Covid-19, the World Health Organization paused the HCQ arm of its multi-centre, multi-drug randomised clinical trial. (Patients who were getting the drug would complete their course, though.) The pause to review safety data from other trials signals that the hype over HCQ was misplaced, and that there is concern about its safety.
The decision, the WHO said, was taken in light of a large observational study published in The Lancet on May 22. The study showed that among one lakh patients from various countries who took the drug (alone or with an antibiotic), the death rate was higher and an increased frequency of irregular heartbeats was observed. Also, the researchers could not confirm any benefit from the drug in Covid-19 patients.
On the same day, the Indian government issued an advisory to expand the pool of personnel who would receive the drug as a preventive measure against the pandemic. The advisory said that cardiovascular side-effects were rare. The basis on which the Centre’s joint task force took this decision included three studies—a retrospective case-control study, an observational study at AIIMS and another investigation from three Central government hospitals—which, as per the advisory, indicated some benefits from taking HCQ for those with high exposure to Covid-19 patients.
Denne historien er fra June 07, 2020-utgaven av THE WEEK.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra June 07, 2020-utgaven av THE WEEK.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Trump And The Crisis Of Liberalism
Although Donald Trump's election to a non-consecutive second term to the US presidency is not unprecedented—Grover Cleveland had done it in 1893—it is nevertheless a watershed moment.
What Will It Take To Clean Up Delhi Air?
IT IS ASKED, year after year, why Delhi’s air remains unbreathable despite several interventions to reduce pollution.
Men eye the woman's purse
A couple of months ago, I chanced upon a young 20-something man at my gym walking out with a women’s sling bag.
When trees hold hands
A filmmaker explores the human-nature connect through the living root bridges
Ms Gee & Gen Z
The vibrant Anuja Chauhan and her daughter Nayantara on the generational gap in romance writing
Vikram Seth-a suitable man
Our golden boy of literature was the star attraction at the recent Shillong Literary Festival in mysterious Meghalaya.
Superman bites the dust
When my granddaughter Kim was about three, I often took her to play in a nearby park.
OLD MAN AND THE SEA
Meet G. Govinda Menon, the 102-year-old engineer who had a key role in surveying the Vizhinjam coast in the 1940s, assessing its potential for an international port
Managing volatility: smarter equity choices in uncertain markets
THE INDIAN STOCK MARKET has delivered a strong 11 per cent CAGR over the past decade, with positive returns for eight straight years.
Investing in actively managed low-volatility portfolios keeps risks at bay
AFTER A ROARING bull market over the past year, equity markets in the recent months have gone into a correction mode as FIIs go on a selling spree. Volatility has risen and investment returns are hurt.
